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Dengue has become a global public health problem and a sensitive diagnostic test for early phase detection can be life saving. An
internally controlled, generic real-time PCR was developed and validated by testing serial dilutions of a DENV positive control
RNA in the presence of a ﬁxed amount of IC with results showing a good linearity (R2 = 0.9967) and a LOD of at least
1.95 × 104 copies/mL. Application of the generic PCR on 136 patient samples revealed a sensitivity of 95.8% and speciﬁcity of
100%. A newly developed multiplex real-time PCR with serotype-speciﬁc probes allowed the serotyping of DENV for 80 out of 92
(87%) generic real-time PCR positive patients. Combined these real-time PCRs oﬀer a convenient diagnostic tool for the sensitive
and speciﬁc quantiﬁcation of DENV in clinical specimens with the possibility for serotyping.
1.Introduction
Mosquito-borneﬂavivirusinfectionssuchasdenguehavera-
pidly spread and are the most signiﬁcant and dreaded infec-
tious diseases in the world, in terms of morbidity and morta-
lity [1, 2]. Recent estimates indicate that over 3.5 billion peo-
ple (∼55%) of the world population live in areas at risk for
dengue[3].Worldwidethereare50–100millioncasesofden-
gue infections per year, which result in 25,000 deaths. Den-
gue has become a major international public health problem
due to the expanding geographic distribution of the vector
in tropical and subtropical countries [1]. Increased interna-
tional travel accompanied with increasing transmission or
re-emergence and changing epidemiology of dengue in vari-
ous (sub) tropical countries contribute to a steady rise in
conﬁrmed dengue among ill-returned travelers [4]. Dengue
is caused by an RNA virus (DENV). DENV is primarily tran-
smitted through bites of the infected Aedes aegypti mosquito
vector. The majority of DENV infections, with any of the
four diﬀerent virus serotypes (DENV-1, DENV-2, DENV-3,
and DENV-4), are mildly asymptomatic and often diﬃcult
to recognize in the early phase of infection because signs and
symptoms are nonspeciﬁc and resemble other febrile ill-
nesses. Only a small number of DENV infections (∼5%) will2 Advances in Virology
result in severe forms of the disease [5, 6]. The most used
diagnostic tools for conﬁrmation of DENV infections are
based on detection of antibodies (Ab) or, recently, NS1 anti-
gen (Ag) detection [7]. However, both Ab and Ag detection
methods do not distinguish the respective DENV serotypes.
Tests based on detection and serotyping of dengue virus oﬀer
the possibility to look better at the association between com-
plicationsofthelifethreateningDHFandDSS,serotype,and
sequential infections [8, 9]. Other real-time PCR assays for
DENV infections are based upon type-speciﬁc primers but
all without internal control (IC) [8, 10, 11]. For reliable de-
tection and to rule out false negative results the use of an IC
is essential [12]. Serotyping of DENV is important because
the lack of cross-reactive immunity for the four diﬀerent
DENV serotypes may lead to a life threatening complication
[9]. In this study we developed and validated an internally
controlled generic real-time PCR for detection and quantiﬁ-
cation of all known DENV serotypes and a multiplex PCR
for discrimination of serotypes based upon serotype-speciﬁc
probes.
2.MaterialsandMethods
2.1. Primers and Probes. All known complete genome seq-
uences of DENV found in GenBank were aligned using Vec-
tor NTI Advance version 10 and ClustalW. The generic pri-
mer pair used for ampliﬁcation of DENV and of DENV-1
invitro RN Af o ruseaspositi v ec o ntr ol(DENVinvitroRNA)
is located in the 3 -UTR region. The DENV generic primers,
theprimersofthenoncompetitive internalcontrolRNA(IC)
(MS2 RNA; Roche Diagnostics), and the probes sequences
for ampliﬁcation and detection are listed in Table 1. The spe-
ciﬁc MS2 RNA primers, probe, and characteristics were de-
signed by us. All primers, probes, and linkers were obtained
from Biolegio (Biolegio, Nijmegen, The Netherlands).
2.2.ConstructionoftheDENV-1InVitroRNAPositiveControl
(DENV In Vitro RNA). For the construction of DENV
in vitro RNA two linkers were designed, named DENV-hyb-1
and DENV-hyb-2. The sequence of DENV-hyb-1 is (DENV
generic primers sequences are in Italic) 5 -
GGTTAGAGGAGACCCCTCCCAAGTCACAACGCAGC-
AGCGGGGCCCAACACCAGGGGAAGCTGTACCCT-
GGTGGTAAGGACTAGAGGTTAGAGGAGACCCCC-
CGCGCAACAATAAACAGCATATTGACGCTGGGAGAG-
ACCAGAGATCCTGCTGTCTC-3  and of DENV-hyb-2 is
5 -GAGACAGCAGGATCTCTGGTCTCTCCCAGCGTC-
AATATGCTGTTTATTGTTGCGCGGGGGGTCTCCTCT-
AACCTCTAGTCCTTACCACCAGGGTACAGCTTCCCC-
TGGTGTTGGGCCCCGCTGCTGCGTTGTGACTTG-
GGAGGGGTCTCCTCTAACC-3 . DENV in vitro RNA was
constructed as described earlier [12, 13].
2.3. RNA Quantiﬁcation. The DENV in vitro RNA and MS2
RNA were quantiﬁed by measuring the optical density at
260nm. Serial dilutions of the RNAs were stored at −70◦C
until use.
2.4. Nucleic Acid Extraction, cDNA, and Generic Real-Time
PCR. DENV in vitro RNA and the 136 patient samples were
e x t r a c t e di nt h ep r e s e n c eo faﬁ x e da m o u n to fI Ca n dc D N A
was made. The IC was spiked before extraction into lysis
buﬀer containing the sample. The extraction of nucleic acids
(NA) was performed on 200μL serum or plasma sample and
5μL IC and eluted in 100μLT E - b u ﬀer [14]. 80μL of the NA
extract was used for cDNA synthesis (RT-reaction) as earlier
described [12] using random primers (Roche Diagnostics)
and the cDNA products were stored at −20◦C. For the pre-
paration of cDNA of DENV in vitro RNA the DENV in vitro
RNA and IC were spiked into the lysis buﬀer containing
DENV negative human serum before extraction. The generic
PCR mix contained 12.5μLo f2 xP r o b e sM a s t e rM i x( R o c h e
Diagnostics), 500nM of primer (each), 300nM of DENV-
generic-MGB probe and 100nM of MS2 probe, and 10μLo f
cDNA (corresponding to 1/12.5 of extraction) in a 25μL
volume. PCR reactions were performed in Bio-Rad iQ5 real-
timemachine(Bio-Rad),asfollowed:10minutesat50◦Cand
10 minutes at 95◦C, followed by 45 cycles of 20s at 95◦C, and
1m i n u t ea t6 0 ◦C for annealing and extension. Data were
analyzed using the Bio-Rad iQ5 software version 2.1 (Bio-
Rad).Apatientsamplewasconsideredpositiveinthegeneric
PCR if the Cq value was below 40. The negative results were
truly negative if the IC was detected in the samples. Other-
wise the sample was considered to be unsuitable for analysis
and the PCR was repeated for a new extraction.
2.5. Serology. Antibodies against DENV were measured us-
ing DENV IgM and IgG Capture ELISA (PANBIO) and by
the method earlier described by Tran et al. [15].
2.6. Clinical Samples. Samples (serum or plasma) from 109
patients with an antibody positive dengue serology and 27
with an antibody negative dengue serology were included.
The 109 patients with an anti-DENV positive serology stra-
tiﬁed in 26 patients with a primary DENV infection and 83
patients with a secondary DENV infection. The 136 patients
couldbe furtherdivided into 3 groups:46 ill-returned travel-
ers (21 primary infections, 16 secondary infections, and 9
antibodies negative) [16], 72 patients from Vietnam (5 pri-
mary infections and 67 secondary infections), [17]a n d1 8
patients from whom 16 patients were antibody and PCR
positive for hepatitis C (HCV) and 2 patients were antibody
and PCR positive for hepatitis A (HAV). The 118 of 136 pa-
tients (46 ill returned travellers and 72 patients from Viet-
nam) were tested by our generic PCR and previous by the
earlier described type-speciﬁc primer PCR [11]. The 18 pa-
tientswithHCVorHAVweretestedonlyinourgenericPCR.
2.7. Serotyping by SYBR-Green. The SYBR Green reactions
were performed in the Bio-Rad iQ5 real-time machine (Bio-
Rad) using the cDNA (10μL) in a 25μL volume consisting
of 12.5μL of iQ SYBR Green Supermix (Bio-Rad), 500nM
generic DENV primer pair. For ampliﬁcation the following
PCR program was used: 10 minutes at 95◦C, followed by 45
cyclesof20sat95◦C,and1minuteat60◦Cforannealingand
extension. The melting temperature (Tm) curve analysis wasAdvances in Virology 3
Table 1: Primers and ﬂuorescence-labeled probes of DENV and noncompetitive IC (MS2 RNA).
Primer or probe Sequence (5 –3 )5   reporter 3  quencher
DENV-F (10546)-generic GGTTAGAGGAGACCCCTCCC
DENV-R (10711)-generic GAGACAGCAGGATCTCTGGTCT
MS2-F CATAAGTTAGATGGCCGTCTGT
MS2-R TAGAGACGACAACCATGCCAAAC
DENV-generic-MGB probe AAACAGCATATTGACGCTGGGA FAM BHQ1
MS2 probe TCCAGACAACGTGCAACATATCGCGACGTATCGTGATATGG HEX BHQ1
DENV-1-MGB probe AACACCATGGGAAGCTGTACCCTG FAM BHQ1
DENV-2-MGB probe GAGATGAAGCTGTAGTCTCACTGG HEX BHQ1
DENV-3-MGB probe TGAGGGAAGCTGTACCTCCTTGCA Texas Red BHQ2
DENV-4-MGB probe CCCGAAGCCAGGAGGAAGCTGTACTCC CY5 BHQ2
Nucleotide numbering for generic primers DENV-F and -R is relative to DENV-1 (reference strain AF226685).
F: forward primer; R: reverse primer; MGB: minor groove binding; BHQ1 or 2: black hole quencher 1 or 2.
performed following the ampliﬁcation and included one
cycle of denaturation at 95◦Cf o r1m i n u t e ,f o l l o w e db y6 0 ◦C
for 1 minute and a ramp to 95◦Ca tar a t eo f0 . 1 ◦Cw i t hc o n -
tinuous ﬂuorescence measurement, using the iQ5 real-time
PCR machine, and the data were analyzed using Bio-Rad
software version 2.1 (Bio-Rad).
2.8.SerotypinginaMultiplexReal-TimePCRAssay. Serotyp-
es were determined using the generic DENV primer pair and
4d i ﬀerent serotype-speciﬁc DENV-probes in one multiplex
PCR reaction. Multiplex PCR reactions were performed as
described for the generic PCR with 500nM of DENV primer
(each)and300nMofeachserotype-speciﬁcDENV-probe1–
4( Table 1).
2.9. Statistical Analysis. Statistical analyses were performed
usingSPSSsoftwareforwindows(version16.0).Frequencies,
means, or medians were calculated to describe background
variables. Agreement was expressed by Cohen’s kappa value.
The type-speciﬁc primer PCR by Laue et al. was used as gold
standard for calculation of sensitivity and speciﬁcity of our
assays [11].
3. Results
3.1. Determination of the Dynamic Range of the Internally
Controlled, Generic Real-Time PCR for DENV. For reliable
detectionandtoruleoutfalsenegativeresultsanICwasused
throughout the whole process of extraction, cDNA synthesis,
and PCR reaction. To determine the dynamic range of the
internal control the extraction, cDNA synthesis, and PCR
procedure were performed on serial dilutions of IC spiked
into the lysis buﬀer containing negative serum. Limiting
dilution results for the IC revealed a detection limit of 10
copies/PCR with a 100% hit rate (Table 2). However, for
reliable detection of the IC in a duplex assay an input corres-
ponding to 500 copies IC/PCR was chosen which had no in-
ﬂuence on the detection limit of DENV in vitro RNA (results
not shown). In subsequent experiments a ﬁxed amount of
6.25 × 103 IC copies was spiked in the lysis buﬀer prior to
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Figure 1: The dynamic range of generic of PCR. Mean Cq-values of
twelve replicates per each 10-fold dilutions of DENV in vitro RNA
extracted with a ﬁxed amount of 6.25 × 103 IC copies in extraction
in the back ground of DENV negative serum and tested in generic
real-time PCR resulting in a dynamic range of 6.25 × 103–6.25 ×
107 copies/mL of DENV in vitro RNA with a regression coeﬃcient
of 0.9967.
extraction and cDNA synthesis. The IC showed good stable
Cq-values (mean Cq-value of 33.34) during the validation.
To determine the dynamic range of the generic PCR, we
spiked 10-fold serial dilutions of DENV in vitro RNA togeth-
e rw i t haﬁ x e da m o u n to fI Ci n t ol y s i sb u ﬀer containing
DENV negative serum prior to extraction and cDNA synthe-
sis. Subsequently 10μL of the cDNA was used in PCR. Li-
miting dilution of DENV in vitro RNA resulted in a quanti-
tativedetectionlimitof103 copies/PCRwitha66.7%hit-rate
(Table 3) and a regression coeﬃcient of 0.9967 with a dyn-
amic range of 6.25 ×103–6.25 × 107 copies/mL (Figure 1).
3.2. Determination of the Lower Limit of Detection (LOD). To
determine the LOD of the generic PCR assay 2-fold serial
dilutions of DENV in vitro RNA were performed with 204 Advances in Virology
Figure 2:MultiplesequencealignmentsofDENV3 UTRregiondeducedfromcompletegenomesequencesofdengueserotypes1–4(DENV
1–4) obtained from GenBank showing primers and probes sequences used in generic and/or multiplex real-time PCR with serotype-speciﬁc
probes for detection of DENV in vitro RNA and DENV in patient samples.
Table 2: Dynamic range of ICa.
IC copies in
extraction
IC copies
in RT
IC copies in
PCRb
Number positives IC (%;
mean Cq-value & SD)
1.25 ×107 107 106 4/4 (100%; 20.74; 0.23)
1.25 ×106 106 105 4/4 (100%; 24.80; 0.43)
1.25 ×105 105 104 4/4 (100%; 27.92; 0.48)
1.25 ×104 104 103 4/4 (100%; 32.08; 0.71)
1.25 ×103 103 102 4/4 (100%; 34.53; 0.56)
1.25 ×102 102 101 4/4 (100%; 36.93; 0.72)
00 0 0 / 4
aThe dynamic range was determined on 10-fold serial dilution of IC spiked
into lysis buﬀer containing DENV negative human serum as background
with 4 replicates for each dilution.
bNumberofcopiescDNA/PCRhasbeencalculatedas1/12.5oftheextracted
RNA, assuming 100% eﬃciency in extraction, reverse transcription (RT),
and PCR.
SD: standard deviation.
replicates per dilution with ﬁxed amount of IC in the back-
ground of DENV negative human serum each separately
spiked in the lysis buﬀer prior to extraction. The LOD for
DENV in vitro RNA was at least 312 copies/PCR correspond-
ing to 1.95 × 104 copies/mL (Table 4).
3.3. Intra- and Inter-Assay Variation. The intra- and inter-
assay variation was measured in four replicates per dilution
of 10-fold dilution series with ﬁxed amount of IC in a back-
ground of DENV negative serum: For intra-assay variation
determined in three runs performed at one day (results not
shown) and for inter-assay variation performed in three 3
runs over 3 consecutive days. The assay variation showed
stable Cq-values for the IC and each serial dilution of DENV
in vitro RNA (Table 5).
3.4. Testing of Clinical Samples. Aﬁ x e da m o u n to fI C( 5μL)
and 200μL of the patient sample were added to the lysis buf-
fer prior to extraction and cDNA synthesis. Overall, the gen-
eric PCR showed a sensitivity of 95.8% and a speciﬁcity of
100% (Table 6). All patient samples with detected IC and
DENVnegativeweretrulynegative.Justfourpatient samples
that tested positive in the type-speciﬁc primer PCR tested
negative in the generic PCR. The patient samples had been
tested earlier by the type-speciﬁc primer PCR [16, 17]a n d
the extra freeze-thaw steps may have aﬀected the quality of
the RNA in these four samples that showed already a high
Cq-value close to 37 or higher in the type-speciﬁc primer
PCR. A lower percentage (62.2%) of the anti-DENV positive
ill-returned travelers had a positive test result in the generic
PCR compared with the anti-DENV positive Vietnamese pa-
tients (95.8%) which correlates with the longer duration of
illness in the ill-returned travelers before seeing a clinician
(Table 6).
3.5. Serotyping by SYBR-Green. Since the SYBR-green real-
timePCRrequiresnotype-speciﬁcprimersorprobes,results
can be obtained with one real-time PCR program for the de-
tectionofthespeciﬁcmeltingcurve(Tm).WeusedthecDNA
from a panel of patients which were known to be infected
with DENV serotype 1 to 4 and who tested previously posi-
tiveinourgenericPCR.TheTm curveshoweverforDENV-1,
DENV-2, DENV-3, and DENV 4 were too close to each other
(84.90◦C, 83.60◦C, 85.80◦C, and 84.70◦C) to enable discrim-
ination between all four serotypes. Also, diﬀerences in the
viral loads inﬂuenced melting temperatures make serotyping
ofDENVbySYBR-greenPCRunreliable(resultsnotshown).
3.6. Serotyping by Multiplex Real-Time PCR with Serotype-
Speciﬁc Probes. The multiplex PCR with serotype-speciﬁcAdvances in Virology 5
Table 3: Dynamic range of generic real-time PCRa.
DENV in vitro
RNA copies in
extraction
DENV in vitro
RNA copies in RT
DENV in vitro
RNA copies in
PCRb
IC copies in
PCRb
Number positives DENV in
vitro RNA (%; mean
Cq-value: SD)
Number positives IC (%;
mean Cq-value: S.D)
1.25 ×107 107 106 500 12/12 (100%; 26.59; 0.54) 12/12 (100%; 35.82; 1.08)
1.25 ×106 106 105 500 12/12 (100%; 30.59; 0.46) 12/12 (100%; 32.67; 0.79)
1.25 ×105 105 104 500 12/12 (100%; 34.35; 1.09) 12/12 (100%; 32.97; 0.74)
1.25 ×104 104 103 500 8/12 (66.7%; 37.22; 0.73) 12/12 (100%; 33.73; 0.63)
1.25 ×103 103 102 500 1/12 (8%; 40.71) 12/12 (100%; 32.24; 0.60)
0 0 0 0 0/12 0/12
aThe dynamic range of the generic PCR was determined on 10-fold dilution series of DENV in vitro RNA in the presence of a ﬁxed amount of IC spiked into
lysis buﬀer containing DENV negative human serum as background and for 12 replicates per dilution.
bNumber of copies cDNA/PCR has been calculated as 1/12.5 of the extracted RNA. assuming 100% eﬃciency in extraction, reverse transcription (RT), and
PCR.
SD: standard deviation.
Table 4: LOD of the generic real-time PCRa.
DENV in vitro RNA copies
in PCRa
IC copies in
PCRb
Number positive DENV in
vitro RNA (%; mean
Cq-value: SD)
Number positive IC (%;
mean Cq-value: SD)
2500 500 20/20 (100%; 35.98; 0.99) 20/20 (100%; 33.43; 0.65)
1250 500 12/20 (60%; 36.96; 1.13) 20/20 (100%; 32.84; 0.53)
1000 500 10/20 (50%; 37.33; 0.94) 20/20 (100%; 33.66; 0.53)
625 500 8/20 (40%; 38.72; 1.82) 20/20 (100%; 32.61; 0.59)
312 500 5/20 (25%; 39.17; 2.67) 20/20 (100%; 32.69; 0.34)
0 0 0/20 0/20
aLOD of the generic PCR was determined by 2-fold dilution series with 20 replicates per dilution of DENV in vitro RNA in the presence of a ﬁxed amount of
IC spiked into lysis buﬀer containing DENV negative human serum as background.
bnumber of copies cDNA/PCR has been calculated as 1/12.5 of the extracted RNA, assuming 100% eﬃciency in extraction, reverse transcription (RT) and
PCR.
LOD: lower limit of detection; SD: standard deviation.
probes was only applied on the cDNAs from the 92 patient
samples which had a positive test result in the generic PCR.
The DENV serotype from these samples was previously
determinedusingthetype-speciﬁcprimerPCR(Table 7)and
was tested blindly in our multiplex PCR. The generic PCR
detected all 4 DENV serotypes. The multiplex PCR with the
type-speciﬁc probes correctly identiﬁed the DENV serotype
in 80 out of the 92 (87%) patient samples. These 12 patient
samples which could not be serotyped in our multiplex assay
had Cq-values close to 38 or higher in the generic PCR. In
three patient samples an infection by two serotypes was de-
tected with the type-speciﬁc primer PCR, whereas by the
multiplex PCR with serotype-speciﬁc probes an infection by
two serotypes was detected in seven out of the 80 patient
samples (Table 7). The viremia levels in ﬁrst serotype were
higher than in the second serotype.
4. Discussion
DENV infections have become a major international public
healthproblemduetotheincreasinggeographic distribution
of the vector [1], the increased international travel accom-
panied with increasing conﬁrmed DENV infection among
ill-returned travelers [4], and the lack of cross-reactive
immunity for the four diﬀerent DENV serotypes and
hyperendemic circulation of the four serotypes in the same
regions. These all are factors that play a signiﬁcant role in the
threat posed by DENV.
An inherent problem in real-time PCR is the presence
of ampliﬁcation inhibitors which may cause false-negative
results. MS2 RNA is an ideal “noncompetitive” internal con-
trol for use as a process control which have already been pro-
ven by other studies. MS2 RNA is commercially available for
any user, and the RNA is a stable, noninfectious and absent
from human clinical samples, and is a noncompetitive con-
trolwhichdoesnotreactwiththeselectedprimersandprobe
for DENV. Our generic real-time PCR assay was capable to
amplify the four known serotypes in one PCR reaction and
showed a good linearity (R2 = 0.9967) with a dynamic range
of 6.25 × 103–6.25 × 107 copies/mL and a LOD of at least
1.95 × 104 copies/mL. The intra- and inter-assay variation
showed stable Cq-values (SD < 0.70) for each 10-fold serial
dilution for DENV in vitro RNA. A viral load of 6.25 × 103
copies/mLcanstillbedetectedwithcertaintyataCq-valueof
40inourgenericPCRin8%ofthecases(Table 3).Therefore,
apatientsamplewasconsideredpositiveinthegenericPCRif
the Cq-value was below 40. The DENV generic primers and
the various probes are based on a highly conserved region
in the 3 -UTR of DENV (Figure 2). DENV genetic diversity
and quasi-species could contribute to PCR accuracy as has6 Advances in Virology
Table 5: Inter-assay variation of generic real-time PCRa.
Run and DENV in
vitroRNA copies in
PCRa
IC copies in PCRb
Number positive DENV
in vitro RNA (%; mean
Cq-value: SD)
Number positive IC (%;
mean Cq-value: SD)
SD between the 3
runs
Run 1
106 500 4/4 (100%; 26.28; 0.43) 4/4 (100%; 36.21; 1.21) 0.27
105 500 4/4 (100%; 30.40; 0.39) 4/4 (100%; 33.10; 1.37) 0.35
104 500 4/4 (100%; 33.78; 0.38) 4/4 (100%; 32.17; 0.30) 0.22
103 500 2/4 (50%; 36.99; 0.37) 4/4 (100%; 33.64; 0.29) 0.65
102 500 0/4 4/4 (100%; 32.47; 0.20) —
00 0 / 4 0 / 4 —
Run 2
106 500 4/4 (100%; 26.71; 0.56) 4/4 (100%; 36.11; 0.84) 0.27
105 500 4/4 (100%; 30.35; 0.19) 4/4 (100%; 32.66; 0.65) 0.35
104 500 4/4 (100%; 34.31; 0.64) 4/4 (100%; 33.32; 0.39) 0.22
103 500 3/4 (75%; 37.08; 0.86) 4/4 (100%; 33.64; 0.92) 0.65
102 500 1/4 (25%; 37.83) 4/4 (100%; 32.73; 1.09) —
00 0 / 4 0 / 4 —
Run 3
106 500 4/4 (100%; 26.79; 0.60) 4/4 (100%; 35.13; 1.06) 0.27
105 500 4/4 (100%; 30.98; 0.50) 4/4 (100%; 32.47; 0.10) 0.35
104 500 4/4 (100%; 34.27; 0.78) 4/4 (100%; 33.24; 0.54) 0.22
103 500 1/4 (25%; 38.17) 4/4 (100%; 33.91; 0.67) 0.65
102 500 0/4 4/4 (100%; 32.59; 0.23) —
00 0 / 4 0 / 4 —
aThe inter-assay variation was determined with 10-fold dilution series of DENV in vitro RNA in the presence of a ﬁxed amount of IC spiked into lysis buﬀer
containingDENVnegativehumanserumasbackgroundandfor4replicatespereachdilution.Thevariationwasdeterminedinthreeseparaterunsperformed
at three diﬀerent days.
bNumber of copies cDNA/PCR has been calculated as 1/12.5 of the extracted RNA, assuming 100% eﬃciency in extraction, reverse transcription (RT), and
PCR.
SD: standard deviation.
been shown for HCV, another member of the family of Flavi-
viruses. However, the variation and the proportion of bio-
logical variants are very low in DENV (unpublished data).
ThetargetofthedescribedDENVPCRisverysmall(157bp)
and we cannot describe quasi-species—like in, for example,
HCV, and moreover there is no external selection pressure
like DENV-speciﬁc antivirals or a vaccine aﬀecting the seq-
uence of the amplicon we used for detection of DENV.
The comparison between the described generic real-time
PCR and the earlier described type-speciﬁc primer PCR us-
ing 118 patient samples showed an excellent concordance
between the two assays with a sensitivity of 95.8% and speci-
ﬁcity of 100% [11]. The patient samples that were not de-
tected in our generic PCR were quantiﬁed with a very low
viral load (about 4.16 × 104 copies/mL) in the type-speciﬁc
primer PCR. The extra freeze-thaw steps caused by using the
same sample tube for serological tests, for the type-speciﬁc
primer PCR assay, and for our generic PCR assay may lead to
degradation of DENV RNA by RNases in the sample. Patient
samples may be divided into aliquots to minimize the eﬀect
of freeze-thawing.
We tried the SYBR-green real-time PCR for serotyping
because it is less expensive and easier to perform compared
to type-speciﬁc primers or probes assays. The SYBR-green
assay results showed that both the viral load and the close
similarity between the four serotypes inﬂuenced the melting
temperatures of each serotype (data not shown), making it
diﬃculttoobtainreliableresults,whichwerealsoseeninpre-
v i o u ss t u d i e s[ 10, 18]. Therefore, we developed a multiplex
real-time PCR assay using four serotype-speciﬁc probes in
one PCR reaction which showed reliable results to discrimi-
nate between the 4 DENV serotypes in patient samples. We
were able to diﬀerentiate between the serotypes in 80 out of
92 patient samples, which had positive generic PCR result,
with the multiplex assay (sensitivity of 87%), and 7 coinfec-
tions with two serotypes were found. The 12 patient samples
which could not be serotyped had Cq-values close to 38 or
higher in the generic PCR which was probably due to the
diﬀerences in sensitivity between the generic and multiplex
PCR and competition within the multiplex PCR. A total of
109 patients had positive antibodies against DENV and 92
patients were positive in our generic PCR. This diﬀerence
may be explained by the relatively high median days of ill-re-
turned travelers after onset of symptoms before visiting a
clinicianandmultiplefreeze-thawsteps.Theill-returnedtra-
velers which had a negative PCR result but positive anti-
bodies against DENV visited a clinician after a median of 6
days (primary infection; range 1 to 12 days) and 8.5 daysAdvances in Virology 7
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Table 7: Serotyping by multiplex real-time PCR with serotype-speciﬁc probes.
Serotype
No. of patients positive in the following assays No. of infections by two serotypes detected by the
following assays (DENV serotypes in infections)c
Type-speciﬁc PCRa Generic PCR Multiplex PCRb Type-speciﬁc PCRa Multiplex PCRb
1 39 Pos (39) 30 3 (1+ 2) 4 (1+4)
2 19 Pos (19) 17 0 1 (2+1)
3 3 Pos (3) 2 0 1 (3+4)
4 31 Pos (31) 31 0 1 (4+2)
t o t a l 9 29 28 0 3 7
Pos: generic PCR can make no distinction between the serotypes.
aThe results were earlier generated by the type-speciﬁc primer PCR according to Laue et al. [11, 16, 17].
bMultiplex real-time PCR with serotype-speciﬁc probes was only done on positive generic PCR results.
cA DENV infection by two serotypes has been assigned to the serotype which signal came up ﬁrst and showed the highest viral load of the two.
(secondary infection; range 4 to 22 days) of illness and possi-
bly the antibodies had emerged after DENV had already dis-
appeared from the blood. It has been postulated that DENV
canbedetectedapproximatelyuntil5daysafteronsetofsym-
ptoms by PCR, regardless of the serotype [11].
Our study describes a speciﬁc, sensitive, and internally
controlled generic real-time PCR assay for early detection of
DENV and the possibility for serotyping by multiplexing.
Screening patients with the internally controlled, generic
PCR assay for DENV and applying the multiplex PCR assay
for typing only on positive sample will be more cost-eﬀective
than performing a typing PCR on all samples. Many of the
published multiplex assays use mixtures of serotype type-
speciﬁc primers and probes which makes the assay less sensi-
tive and more expensive [10]. Other multiplex PCRs are not
genuine multiplex PCR assays because they consist of two
separateduplexPCRassays,eachwithaprobepairforDENV
1 – 3o rD E N V2 – 4[ 18].
The described assays are an important complementary
tool for diagnosis of DENV in patients in the early phase of
disease.
Abbreviations
DENV: Dengue virus
IC: Internal control
HCV: Hepatitis C
HAV: Hepatitis A
PCR: Polymerase chain reaction
RT: Reverse transcription
DHF: Dengue hemorrhagic fever
DSS: Dengue shock syndrome
NS1: Nonstructural 1 protein
Ab: Antibody
Ag: Antigen
LOD: Lower limit of detection
Cq-value: Cycle for quantiﬁcation.
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